A long survival patient of anaplastic thyroid carcinoma treated with lenvatinib. Issue 3 (June 2022)

• Record Type: Journal Article
• Authors: Hamamoto, Takao; Kono, Takashi; Taruya, Takayuki; Ishino, Takashi; Ueda, Tsutomu; Takeno, Sachio
• Is Part Of: Auris nasus larynx. Volume 49:Issue 3(2022)
• Page Start: 515
• Page End: 519
• Publication Date: 2022-06
• Subjects: Anaplastic thyroid carcinoma -- Lenvatinib -- Survival period; Otolaryngology -- Periodicals; Electronic journals; 616
• DOI: 10.1016/j.anl.2020.10.005
• Languages: English
• ISSNs: 0385-8146

Abstract

Abstract: Anaplastic thyroid carcinoma (ATC) accounts for 1–2% of all malignant thyroid tumors. There are only a small number of patients with ATC and most of them die within 6 months after diagnosis, making it difficult to establish a standard treatment strategy. Although multimodal therapy, including radical surgery, radiotherapy, and chemotherapy, has been introduced, the survival rate remains poor. The use of molecular-targeted drugs for cancer therapy has become widely popular. Lenvatinib, a new molecular-targeted anticancer drug, is a multi-targeted receptor tyrosine kinase inhibitor (TKI). We report a rare case of a patient with ATC (T4N0M0) who responded extremely well to the administration of lenvatinib after radical surgery. Although ATC is one of the most fatal neoplasms, lenvatinib is a promising drug.